DRRX

DURECT Corporation

DRRX | $0.9071 7.55% 7.02% 140K

(0.0% 1d) (-30.7% 1m) (-78.7% 1y) (0.0% 2d) (4.8% 3d) (1.1% 7d) (349.03% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 28,152,738
http://www.durect.com
Sec Filling | Patents | 90 employees

(US) DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

t-cell analgesic hepatitis pain relief ceiling

add to watch list Paper trade email alert is off

Press-releases

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-27 (Crawled : 20:00) - prnewswire.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| -34.33% | O: -6.72% H: 4.0% C: -3.2%
business year corporation update financial results

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Published: 2024-03-20 (Crawled : 21:00) - prnewswire.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| -31.25% | O: -2.34% H: 2.4% C: 0.0%
business year corporation update financial results

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-07 (Crawled : 00:00) - prnewswire.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| 24.65% | O: -0.79% H: 10.19% C: 7.94%
conference life corporation sciences

Long-Acting Drug Delivery Technologies and Services Industry Outlook, 2033 - Asia-Pacific Expected to Register the Highest CAGR of 12.70%, with Long-Acting Injectables Dominating
Published: 2023-12-28 (Crawled : 12:00) - prnewswire.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| 67.62% | O: 0.95% H: 13.53% C: 12.62%
drug services expected

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-13 (Crawled : 21:00) - prnewswire.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| 67.36% | O: -0.91% H: 4.47% C: 4.41%
business corporation update financial results

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Published: 2023-09-07 (Crawled : 14:30) - biospace.com/
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| -69.55% | O: -1.38% H: 2.81% C: 1.75%
hepatitis corporation trial

DURECT Corporation Announces Presentations in Upcoming Investor Conferences
Published: 2023-08-31 (Crawled : 21:00) - durect.com
DRRX | $0.9071 7.55% 7.02% 140K

Health Technology

| -71.24% | O: 0.0% H: 0.98% C: -0.16%
corporation